CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) announced it will release its third-quarter 2025 financial results on Tuesday, November 4, 2025, ahead of the opening of U.S. financial markets.
The company’s management will hold a live webcast at 8 a.m. Eastern Time to discuss financial and operational performance. Investors and analysts can access the presentation through the Investor Relations section of Madrigal’s website. Registration is advised at least 15 minutes before the webcast begins, and a replay will be available roughly two hours afterward.
Madrigal, a clinical-stage biopharmaceutical company headquartered in Conshohocken, is dedicated to developing therapies for metabolic dysfunction-associated steatohepatitis (MASH), a progressive liver disease previously known as nonalcoholic steatohepatitis (NASH).
The company’s flagship therapy, Rezdiffra (resmetirom), is the first and only treatment approved by both the U.S. Food and Drug Administration and the European Commission for MASH patients with moderate to advanced fibrosis (F2 to F3). Rezdiffra is a once-daily, oral, liver-directed thyroid hormone receptor beta (THR-β) agonist designed to target the underlying metabolic and fibrotic mechanisms driving the disease.
Madrigal is also conducting a Phase 3 outcomes trial to assess Rezdiffra’s potential benefits in patients with compensated MASH cirrhosis (F4c). The study is expected to further define the drug’s long-term impact on disease progression and patient outcomes.
The upcoming financial report is likely to provide new insights into Rezdiffra’s commercial performance and Madrigal’s strategic plans as it advances its leadership position in liver disease therapeutics.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.